|
|
| | GLPG-0778 Basic information |
| Product Name: | GLPG-0778 | | Synonyms: | GLPG-0778;Solcitinib;N-(5-(4-(3,3-Dimethylazetidine-1-carbonyl)phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl)cyclopropanecarboxamide;Solcitinib (GSK2586184);G 154578;GSK 2586184;GSK 2586184A;Solcitinib（GLPG0778） | | CAS: | 1206163-45-2 | | MF: | C22H23N5O2 | | MW: | 389.45 | | EINECS: | | | Product Categories: | API | | Mol File: | 1206163-45-2.mol |  |
| | GLPG-0778 Chemical Properties |
| density | 1.40±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMF: 2 mg/ml; DMSO: 5 mg/ml; Ethanol: 1 mg/ml | | form | A crystalline solid | | pka | 7.99±0.20(Predicted) |
| | GLPG-0778 Usage And Synthesis |
| Description | Solcitinib is a JAK1 inhibitor (IC50 = 9.8 nM). It is greater than 10-fold selective for JAK1 over JAK2, JAK3, and TYK2. |
| | GLPG-0778 Preparation Products And Raw materials |
|